Waypoint Bio co-founders and Xinchen Wang (L) and David Phizicky (Credit: Waypoint Bio)

June 27, 2024 07:00 AM EDTUpdated 05:14 PM

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

Ryan Cross

Senior Science Correspondent

Therapies made from a patient’s own immune cells have spurred medical miracles for many people with advanced blood cancers, but getting those CAR-T cell therapies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO